Quest for the right Drug
פרוברה 5 מ"ג PROVERA 5 MG (MEDROXYPROGESTERONE ACETATE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
טבליה : TABLETS
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8 Undesirable effects The table below provides a listing of adverse drug reactions with frequency based on all-causality data from Phase 3 clinical studies that evaluated efficacy and safety of DMPA in gynaecology. Those most frequently (>5%) reported adverse drug reactions were dysfunctional uterine bleeding (19%), headache (12%) and nausea (10%). The following lists of adverse reactions are listed within the organ system classes, under headings of frequency (number of patients expected to experience the reaction), using the following categories: Very common (≥1/10) Common (≥1/100 to <1/10); Uncommon (≥1/1000 to <1/100); Rare (≥1/10,000 to <1/1000); Very rare (<1/10,000); Not known (cannot be estimated from the available data). System Organ Very Common Common Uncommon Rare ≥ Very Frequency Not Class ≥1/10 ≥ 1/100 to ≥ 1/1000 to 1/10,000 to Rare Known (cannot be < 1/10 < 1/100 < 1/1000 < estimated from 1/10,000 available data) Immune system Drug Anaphylactic reaction, disorders hypersensitivity Anaphylactoid reaction, Angioedema Endocrine Anovulation disorders Psychiatric Depression, disorders Insomnia, Nervousness Nervous system Headache Dizziness Somnolence disorders Vascular Embolism and disorders thrombosis Gastrointestinal Nausea disorders Skin and Alopecia, Acne, Hirsutism Rash subcutaneous Urticaria tissue disorders Pruritus Reproductive Dysfunctional Cervical Galactorrhoea Amenorrhoea, Uterine system and uterine bleeding discharge, cervical erosion breast disorders (irregular, Breast pain, increase, Breast decrease, tenderness spotting) General Temperature Oedema, Fluid disorders and elevation, retention administration Fatigue site conditions System Organ Very Common Common Uncommon Rare ≥ Very Frequency Not Class ≥1/10 ≥ 1/100 to ≥ 1/1000 to 1/10,000 to Rare Known (cannot be < 1/10 < 1/100 < 1/1000 < estimated from 1/10,000 available data) Investigations Weight Glucose tolerance increased decreased, Weight decreased Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form https://sideeffects.health.gov.il/
שימוש לפי פנקס קופ''ח כללית 1994
Secondary amenorrhea, dysfunctional uterine bleeding, ovarian insufficiency, addition to menopausal estrogen replacement therapy
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה שאושרה לשימוש כללי בקופ'ח
מידע נוסף